Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on April 8, 2025
BON Announces Unlocking Broccoli's Nutritional Power: Advanced Delivery System for Glucoraphanin Activation
GlobeNewswire
·
April 8, 2025
XI’AN, China, April 08, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or "the Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, announced our biotech innovation addresses …
Major Medicaid and ACA Marketplace changes could be coming: What consumers need to know now
GlobeNewswire
·
April 8, 2025
Minneapolis, MN, April 08, 2025 (GLOBE NEWSWIRE) -- Millions of people who rely on Medicaid and ACA Marketplace coverage (Obamacare) could be impacted by sweeping federal policy changes under consideration. Healthinsurance.org is closely tracking these …
Avadel Pharmaceuticals Provides Update at Needham Virtual Healthcare Conference
GlobeNewswire
·
April 8, 2025
DUBLIN, April 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today presented at the 24th Annual Needham Virtual Healthcare Conference. The Company …
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
GlobeNewswire
·
April 8, 2025
Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive …
Communiqué de presse : Publication dans le NEJM de données de phase III illustrant le bénéfice du tolebrutinib sur la progression du handicap dans la sclérose en plaques
GlobeNewswire
·
April 8, 2025
Publication dans le NEJM de données de phase III illustrant le bénéfice du tolebrutinib sur la progression du handicap dans la sclérose en plaques Les résultats de l’étude de phase III HERCULES montrent que le tolebrutinib retarde la progression du …
Developmental and Epileptic Encephalopathies Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight
GlobeNewswire
·
April 8, 2025
New York, USA, April 08, 2025 (GLOBE NEWSWIRE) -- Developmental and Epileptic Encephalopathies Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight The treatment paradigm for DEE is expected to evolve in the coming years. …
Press release: SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
GlobeNewswire
·
April 8, 2025
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES Ghent, Belgium, 8 April 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, …
IND HEMP and National Hemp Association (NHA) Introduce Groundbreaking Nutritional Approach to Malaria Relief with Hemp Seed Oil
GlobeNewswire
·
April 8, 2025
Fort Benton, Montana and Washington, DC, April 08, 2025 (GLOBE NEWSWIRE) -- IND HEMP, the leading industrial hemp producer and processor in the United States, and the National Hemp Association (NHA) today announced a pioneering, nutrition-based strategy to …
Cerevance Presents Positive Results from Phase 1 Study of CVN293 at American Academy of Neurology 2025 Annual Meeting
GlobeNewswire
·
April 8, 2025
CVN293 was generally well-tolerated in healthy volunteers with evidence of robust brain penetration, supporting utility of KCNK13 inhibitors for neurodegenerative diseases characterized by neuroinflammation Additional AAN 2025 poster presentations …
Neurona Therapeutics Presents Positive Clinical Data Update from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy at American Academy of Neurology Annual Meeting
GlobeNewswire
·
April 8, 2025
–EFFICACY: 92% median reduction in disabling seizures during 7-12-month efficacy endpoint period, and 80% (4/5) of patients responding with >75% seizure reduction in Cohort 1. –DURABILITY: All responders (4/4) in Cohort 1 continue to have durable seizure …
Emerging IgAN Therapies Bring Hope – But Patients Still Face Emotional and Financial Barriers, According to Spherix Global Insights
GlobeNewswire
·
April 8, 2025
EXTON, PA, April 08, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights has released the first edition of its new Patient Dynamix™: IgA Nephropathy (US) series, delivering a comprehensive look at the IgAN patient journey amid a rapidly evolving therapeutic …
Better Choice Company Revises Payment Date for Stock Dividend of 0.35 per Share for Each Share Held for Stockholders of Record as of April 17, 2025
GlobeNewswire
·
April 8, 2025
TAMPA, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- Better Choice Company, Inc. (NYSE American: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, announced on April 7, 2025 that its Board of Directors has approved a stock dividend of …
Cosmos Health Launches Sky Premium Life in Albania through Partnership with Pharma Cell; Secures Initial $300,000 Order
GlobeNewswire
·
April 8, 2025
CHICAGO, April 08, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R…
iCAD Expands Executive Leadership with Appointment of Mark Koeniguer as Chief Commercial Officer
GlobeNewswire
·
April 8, 2025
NASHUA, N.H., April 08, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today announced …
Clinical Study Finds Saw Palmetto Extract Supports Appearance of Hair Thickness in Over 50% of Men
GlobeNewswire
·
April 8, 2025
Fort Lauderdale, FL, April 08, 2025 (GLOBE NEWSWIRE) -- Hair today, gone tomorrow? You’re not alone. A recent survey of Life Extension male customers* revealed that more than half of men (54%) experience thinning hair, with nearly a quarter (24%) noticing …
AscellaHealth Showcases Rare Disease Expertise and Comprehensive Specialty Pharmaceutical Solutions at World Orphan Drug Congress USA 2025
GlobeNewswire
·
April 8, 2025
BERWYN, Pa., April 08, 2025 (GLOBE NEWSWIRE) -- AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, proudly announces its role as a Silver Sponsor at the World Orphan Drug Congress USA (WODC), …
CORRECTION: Mitolyn
GlobeNewswire
·
April 8, 2025
In a release issued under the same headline on March 31, 2025 by Mitolyn, please note that the headline has been edited from "Mitolyn Reviews (CRITICAL DOCTOR BREAKDOWN): Experts Reveal the Cellular Science Behind the Mitolyn Hype" to "Mitolyn 2025 …
AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
GlobeNewswire
·
April 8, 2025
LONDON and PHOENIX, April 08, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has …
Codex Labs OTC Bia Eczema Relief Lotion Is Awarded Seal of Acceptance from National Eczema Association and Microbiome-Friendly Certification from MyMicrobiome
GlobeNewswire
·
April 8, 2025
San Jose, CA, USA, April 08, 2025 (GLOBE NEWSWIRE) -- Codex Labs, a Silicon Valley skintech company, announced that its over-the-counter (OTC) Bia Eczema Relief Lotion has been awarded the Seal of Acceptance by the National Eczema Association (NEA). The …
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
April 8, 2025
MIAMI, April 08, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved …